EMA Warns PRIME Applicants Over Missing Pediatric Investigation Plans
This article was originally published in SRA
Executive Summary
Two thirds of the applications submitted for entry into the European Medicines Agency's new PRIME (priority medicines) scheme in the month after its launch were missing a pediatric investigation plan or a PIP waiver.